Biktarvy Label Update Adds Data on Safety, Efficacy in Pregnant HIV Patients
The approval was based on data from an open-label clinical trial that included 33 virologically-suppressed pregnant adults.
Source: empr.com
📰 Clinical Development News
Page 25 - Clinical Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development. Real-time updates on events, politics, business and more.
Ocugen to Present on Modifier Gene Therapy Platform at
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,...
Source: globenewswire.com
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
MALVERN, Pa., April 26, 2024 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the...
Source: marketscreener.com
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
MALVERN, Pa., April 26, 2024 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the...
Source: marketscreener.com
FDA Approves Biktarvy Label Update With Data for Pregnant Adults With HIV
26.04.2024 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir ... Seite 1
Jared Baeten Gilead Sciences Inc Drug Administration Clinical Development Human Services Us Department Of Health
Source: wallstreet-online.de
Nihon Kohden : Announces Change in Directors
These documents have been translated from Japanese originals for reference purposes only. In the event of any discrepancy between these translated documents and the Japanese originals,...
Source: marketscreener.com
Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
Source: onclive.com
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
Repare Therapeutics Inc. , a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the...
Source: marketscreener.com
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
Repare Therapeutics Inc. ("Repare" or the "Company") , a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual...
South Africa Lloydm Segal Stevenh Stein Todd Foley University Of Witwatersrand Us Clinical Development
Source: lelezard.com
Labcorp Announces 2024 First Quarter Results
Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year:Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7%Diluted EPS:...
United States Adam Schechter Early Development Research Laboratories Commercialization Services Clinical Development Bioreference Health
Source: marketscreener.com